摘要
目的:评价布地奈德(BUD)混悬液雾化吸入治疗小儿急性感染性喉炎(AIL)的临床效果。方法:选2013年5月—2016年5月我院收治的AIL患儿86例,随机分为对照组和观察组,每组43例,其中对照组采用地塞米松静脉注射治疗,观察组采用BUD混悬液雾化吸入治疗。比较两组的治疗效果和不良反应发生率。结果:与对照组相比,观察组犬吠样咳嗽、声嘶、喉鸣等临床症状消失时间及住院天数明显缩短(P<0.05),愈显率显著提高(83.72%VS 60.46%,P<0.05),而不良反应明显减少(6.98%VS 23.25%,P<0.05)。结论:雾化吸入BUD混悬液治疗小儿AIL起效快,疗程短,不良反应少。
Objective: To evaluate the efficacy of budesonide (BUD) suspension liquid atomization inhalation on acute infectious laryngitis (AIL) in children.Methods: 86 cases of children with AIL in our hospital from May 2013 to May 2016, were randomly divided into control group and observation group, each group of 43 cases. The control group was treated with intravenous dexamethasone, and the observation group used BUD aerosol inhalation therapy. The treatment effect and incidence rate of adverse reactions of the two groups were compared. Results: Compared with the control group, barking cough, hoarseness, throat singing and other clinical symptoms disappeared time and length of stay in the observation group were shortened significantly (P<0.05), effectiveness rate was higher (83.72% vs 60.46%, P<0.05). Adverse reactions in the observation group were significantly less than those in the control group (6.98% vs 23.25%, P<0.05).Conclusion: The effect of BUD atomization inhalation in the treatment of children with AIL is fast, short course of disease,and less adverse reaction.
作者
陈学才
CHEN Xue-cai(Pediatric, Le'an People's Hospital, Fuzhou Jiangxi 344300, China)
出处
《药品评价》
CAS
2016年第24期27-28,共2页
Drug Evaluation
